Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici

Castellino, G.

Risultato della ricerca: Article

1 Citazione (Scopus)

Abstract

The purpose of innovative therapeutic approaches for type 2 diabetes mellitus is to customize the antidiabetic treatment to each patient's need, in order to intensify glucose-lowering effects without hypoglycemia, reduce adverse events, and prevent cardiovascular events. Glucagon-like peptide 1 (GLP-1) analogues are effective drugs in the treatment of type 2 diabetes, and they also seem to have beneficial effects on several risk factors for cardiovascular disease, leading to cardiovascular risk reduction independent of hypoglycemic effects. Among these new drugs, liraglutide, a GLP-1 analogue with a homology of 97% to native GLP-1, exerts an effect on body weight, lipid parameters, blood pressure and endothelial function, inflammatory markers, markers of oxidative stress, and subclinical atherosclerosis. The results of numerous studies and metaanalyses on liraglutide suggest that this drug improves quality of life through the reduction in hypoglycemic episodes, glucose effectiveness, and the improvement of cardiovascular risk factors.
Lingua originaleItalian
pagine (da-a)253-258
Numero di pagine6
RivistaGiornale Italiano di Cardiologia
Volume17
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cita questo

Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici. / Castellino, G.

In: Giornale Italiano di Cardiologia, Vol. 17, 2016, pag. 253-258.

Risultato della ricerca: Article

@article{e5f5ce4046694965b37ebcf5686a2835,
title = "Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici",
abstract = "The purpose of innovative therapeutic approaches for type 2 diabetes mellitus is to customize the antidiabetic treatment to each patient's need, in order to intensify glucose-lowering effects without hypoglycemia, reduce adverse events, and prevent cardiovascular events. Glucagon-like peptide 1 (GLP-1) analogues are effective drugs in the treatment of type 2 diabetes, and they also seem to have beneficial effects on several risk factors for cardiovascular disease, leading to cardiovascular risk reduction independent of hypoglycemic effects. Among these new drugs, liraglutide, a GLP-1 analogue with a homology of 97{\%} to native GLP-1, exerts an effect on body weight, lipid parameters, blood pressure and endothelial function, inflammatory markers, markers of oxidative stress, and subclinical atherosclerosis. The results of numerous studies and metaanalyses on liraglutide suggest that this drug improves quality of life through the reduction in hypoglycemic episodes, glucose effectiveness, and the improvement of cardiovascular risk factors.",
keywords = "Cardiometabolic markers; Cardiovascular risk; Carotid intima-media thickness; Liraglutide; Type 2 diabetes mellitus; Cardiology and Cardiovascular Medicine",
author = "{Castellino, G.} and Giuseppe Montalto and Alessandro Parrino and Manfredi Rizzo and Patti, {Angelo Maria} and Dragana Nikolic and Giglio, {Rosaria Vincenza} and Marcello Noto",
year = "2016",
language = "Italian",
volume = "17",
pages = "253--258",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",

}

TY - JOUR

T1 - Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici

AU - Castellino, G.

AU - Montalto, Giuseppe

AU - Parrino, Alessandro

AU - Rizzo, Manfredi

AU - Patti, Angelo Maria

AU - Nikolic, Dragana

AU - Giglio, Rosaria Vincenza

AU - Noto, Marcello

PY - 2016

Y1 - 2016

N2 - The purpose of innovative therapeutic approaches for type 2 diabetes mellitus is to customize the antidiabetic treatment to each patient's need, in order to intensify glucose-lowering effects without hypoglycemia, reduce adverse events, and prevent cardiovascular events. Glucagon-like peptide 1 (GLP-1) analogues are effective drugs in the treatment of type 2 diabetes, and they also seem to have beneficial effects on several risk factors for cardiovascular disease, leading to cardiovascular risk reduction independent of hypoglycemic effects. Among these new drugs, liraglutide, a GLP-1 analogue with a homology of 97% to native GLP-1, exerts an effect on body weight, lipid parameters, blood pressure and endothelial function, inflammatory markers, markers of oxidative stress, and subclinical atherosclerosis. The results of numerous studies and metaanalyses on liraglutide suggest that this drug improves quality of life through the reduction in hypoglycemic episodes, glucose effectiveness, and the improvement of cardiovascular risk factors.

AB - The purpose of innovative therapeutic approaches for type 2 diabetes mellitus is to customize the antidiabetic treatment to each patient's need, in order to intensify glucose-lowering effects without hypoglycemia, reduce adverse events, and prevent cardiovascular events. Glucagon-like peptide 1 (GLP-1) analogues are effective drugs in the treatment of type 2 diabetes, and they also seem to have beneficial effects on several risk factors for cardiovascular disease, leading to cardiovascular risk reduction independent of hypoglycemic effects. Among these new drugs, liraglutide, a GLP-1 analogue with a homology of 97% to native GLP-1, exerts an effect on body weight, lipid parameters, blood pressure and endothelial function, inflammatory markers, markers of oxidative stress, and subclinical atherosclerosis. The results of numerous studies and metaanalyses on liraglutide suggest that this drug improves quality of life through the reduction in hypoglycemic episodes, glucose effectiveness, and the improvement of cardiovascular risk factors.

KW - Cardiometabolic markers; Cardiovascular risk; Carotid intima-media thickness; Liraglutide; Type 2 diabetes mellitus; Cardiology and Cardiovascular Medicine

UR - http://hdl.handle.net/10447/197851

UR - http://www.giornaledicardiologia.it/r.php?v=2214&a=23896&l=325590&f=allegati/02214_2016_04/fulltext/03.Giglio%20(253-258).pdf

M3 - Article

VL - 17

SP - 253

EP - 258

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

ER -